IP Library Granted Patent US 7,659,075
Granted Patent B2
US 7,659,075 · App. 10/496,096 · Granted Feb 9, 2010

Method for the diagnosis of sepsis with determination of soluble cytokeratin fragments

Assignee: B.R.A.H.M.S Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,659,075
App. No.
10/496,096
Granted
Feb 9, 2010
Kind
B2
Abstract

Method for early differential diagnosis and detection, for prognosis and assessment of the severity and for therapy-accompanying assessment of the course of sepsis and sepsis-like systemic infections, in which, preferably with additional determination of at least one further parameter suitable for sepsis diagnosis, the amount of soluble cytokeratin fragments, in particular of CYFRA 21-1, TPS, TPA and/or sCY1F, in a biological fluid of a patient in whom a sepsis is present or a sepsis is suspected is determined and conclusions with regard to the presence, the expected course, the severity and/or the success of initiated measures for the therapy of the sepsis are drawn from the determined amount of soluble cytokeratin fragments.

Claims (4)

1. A method for diagnosis and detection of sepsis, comprising providing a biological fluid of a patient in whom sepsis is suspected based on clinical findings and elevated levels of procalcitonin in said patient; and determining the amount of cytokeratin fragment 21-1 (CYFRA 21-1) in said fluid wherein an elevated concentration of CYFRA 21-1 in said fluid as compared to healthy individuals is indicative of sepsis.

2. The method of claim 1 , wherein the amount of CYFRA 21-1 is determined by an immunodiagnostic assay method.

3. The method of claim 1 , wherein said biological fluid is patient's serum.

4. The method of claim 1 , wherein CYFRA 21-1 in an amount greater than 1 ng/ml is indicative of sepsis.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2013
From: BERGMANN, ANDREAS, DR
To: SPHINGOTEC GMBH
Reel/Frame 031030/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2013
From: B.R.A.H.M.S. GMBH
To: BERGMANN, ANDREAS, DR.
Reel/Frame 031013/0914 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2011
From: B.R.A.H.M.S AKTIENGESELLSCHAFT
To: B.R.A.H.M.S GMBH
Reel/Frame 025697/0943 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2004
From: BERGMANN, ANDREAS
To: B.R.A.H.M.S. AKTIENGESELLSCHAFT
Reel/Frame 016083/0921 →
Priority Claims (1)
EP 01128851 · Dec 4, 2001 · regional
Continuity (1)
Related Publication 20050106645A1 · May 19, 2005